NCT05367739View on ClinicalTrials.gov

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

May 1, 2022

Study Completion Date

July 1, 2023

Conditions
Breast NeoplasmsHER2-positive Breast Cancer
Trial Locations (1)

410013

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER

NCT05367739 - Real World Study on the Efficacy and Safety of Anti-HER2 Therapy | Biotech Hunter | Biotech Hunter